1. Introduction {#sec1-cancers-11-00778}
===============

The long non-coding RNAs (lncRNAs) are non-protein-coding RNAs ≥ 200 bp in length, transcribed by RNA polymerase II. LncRNAs can be capped, polyadenylated and spliced, but they lack a functional open reading frame. It is estimated that approximately 27% (i.e., up to 60,000) of the annotated genes in the human genome encode lncRNAs, while the number of protein-coding genes ranges from 20,000 to 25,000 \[[@B1-cancers-11-00778],[@B2-cancers-11-00778]\]. They are largely involved in a myriad of cellular functions, regulating gene expression at the transcriptional, post-transcriptional, and epigenetic level \[[@B1-cancers-11-00778],[@B3-cancers-11-00778]\]. LncRNAs have emerged as critical components of cancer pathophysiology, being involved in one or more hallmarks of cancer, such as proliferation and metastasis \[[@B4-cancers-11-00778],[@B5-cancers-11-00778]\]. They can act either as oncogenes or tumor suppressors, or indirectly through interaction with oncogenes and tumor suppressors, such as MYC proto-oncogene (MYC) and tumor protein p53 (TP53), respectively \[[@B4-cancers-11-00778],[@B5-cancers-11-00778]\].

One of the most well-studied lncRNAs is *HOX transcript antisense RNA* (*HOTAIR*) which is located within the *HOMEOBOX C* (*HOXC*) gene cluster on chromosome 12q13.13 \[[@B6-cancers-11-00778]\]. *HOTAIR* is 2158 bp long and consists of six exons. *HOTAIR* orthologs are restricted to eutherian mammals \[[@B7-cancers-11-00778]\]. *HOTAIR* is known to bind to the Polycomb Repressive Complex 2 (PRC2) and the histone H3K4 demethylase LSD1, and serves as a scaffold to assemble these regulators at the *HOXD* gene cluster, where it establishes a transcriptionally repressive chromatin structure, thereby resulting in epigenetic repression of the *HOXD* gene locus \[[@B8-cancers-11-00778]\]. *HOTAIR* has been shown to function as an oncogene since its expression is dysregulated in multiple types of cancers, including breast, lung, liver, renal, hepatocellular, gastric, nasopharyngeal, cervical, colorectal, bladder, pancreatic cancer, as well as melanoma, leukemia, etc. \[[@B9-cancers-11-00778],[@B10-cancers-11-00778],[@B11-cancers-11-00778],[@B12-cancers-11-00778],[@B13-cancers-11-00778]\]. Furthermore, *HOTAIR* is suggested to promote cancer progression and contribute largely to cancer cell invasion and metastasis \[[@B14-cancers-11-00778],[@B15-cancers-11-00778],[@B16-cancers-11-00778],[@B17-cancers-11-00778]\]. The multifunctional *HOTAIR* is implicated in the different aspects of cancer pathophysiology by regulating gene expression at the transcriptional, post-transcriptional, and epigenetic level \[[@B14-cancers-11-00778],[@B18-cancers-11-00778],[@B19-cancers-11-00778],[@B20-cancers-11-00778]\]. Of note, several studies suggest that *HOTAIR* expression is highly predictive of cancer patient survival rates in diverse cancer types \[[@B21-cancers-11-00778],[@B22-cancers-11-00778],[@B23-cancers-11-00778],[@B24-cancers-11-00778],[@B25-cancers-11-00778],[@B26-cancers-11-00778],[@B27-cancers-11-00778],[@B28-cancers-11-00778],[@B29-cancers-11-00778]\].

Herein, we conducted a comprehensive and updated meta-analysis to further investigate the prognostic value of *HOTAIR* expression for cancer patients. The potential clinical applications of our findings are also discussed towards the prognostic application of *HOTAIR* to multiple and different types of cancers.

2. Results {#sec2-cancers-11-00778}
==========

2.1. Study Selection and Charasteristics of Eligible Studies {#sec2dot1-cancers-11-00778}
------------------------------------------------------------

A total of 264 relevant published scientific studies were retrieved from the biomedical literature (up to 31 December 2018). According to the inclusion and exclusion criteria, 53 studies were ultimately included in this meta-analysis, as shown in [Figure 1](#cancers-11-00778-f001){ref-type="fig"}. The main characteristics of the included studies are summarized in [Table 1](#cancers-11-00778-t001){ref-type="table"}, where the following information was recorded: first author's surname; year of publication; country of origin; type of cancer; follow-up period (in months); total number of patients; detection assay for *HOTAIR* expression; HR and the corresponding 95% CI for overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS), metastasis-free survival (MFS); survival data extraction method; and specimen type. Collectively, 4873 patients from 55 cohorts between 2010 and 2018 were included. The included studies reported a follow-up period ranging from 36 to 276 months. The level of *HOTAIR* expression was measured with quantitative reverse transcription polymerase chain reaction (qRT-PCR) in all of the included studies, except one where *HOTAIR* expression was estimated by microarrays ([Table 1](#cancers-11-00778-t001){ref-type="table"}).

2.2. Association between High HOTAIR Expression and Overall Survival in Diverse Cancers {#sec2dot2-cancers-11-00778}
---------------------------------------------------------------------------------------

A total of 45 studies were included for overall survival (OS). We found a statistically significant relationship between elevated *HOTAIR* expression and poor OS (random-effects model: pooled HR = 2.00; 95% CI: 1.77--2.27; *p* \< 0.001), with marginally moderate heterogeneity (I^2^ = 50.2%; P~h~ \< 0.001) ([Figure 2](#cancers-11-00778-f002){ref-type="fig"}a). Subgroup analyses were performed based on the type of cancers, ethnic group, and data extraction method ([Figure 3](#cancers-11-00778-f003){ref-type="fig"}). When the studies were classified based on major cancer types (according to NCBI's medical subject headings (MeSH) \[[@B77-cancers-11-00778]\]), a significant association was found between *HOTAIR* overexpression and poorer OS in solid cancers, such as gastrointestinal cancers (fixed-effects model: pooled HR = 1.96; 95% CI: 1.65--2.35; *p* \< 0.001), liver cancers (fixed-effects model: pooled HR = 2.84; 95% CI: 1.83--4.40; *p* \< 0.001), head and neck cancers (fixed-effects model: pooled HR = 1.93; 95% CI: 1.53--2.43; *p* \< 0.001), and urogenital cancers (random-effects model: pooled HR = 2.11; 95% CI: 1.58--2.84; *p* \< 0.001), as well as liquid cancers, including leukemia (fixed-effects model: pooled HR = 2.32; 95% CI: 1.56--3.44; *p* \< 0.001) and lymphoma (fixed-effects model: pooled HR = 3.13; 95% CI: 1.22--8.04; *p* \< 0.001). Of note, the heterogeneity was reduced significantly in the individual cancer types ([Figure 3](#cancers-11-00778-f003){ref-type="fig"}a). In the subgroup analysis based on ethnicity, a statistically significant worse OS was observed for Asians (fixed-effects model: pooled HR = 2.04; 95% CI: 1.81--2.31; *p* \< 0.001). Regarding the Caucasian subgroup, despite the relatively high HR, the relationship cannot be considered robust because the *p*-value is slightly higher that the cutoff value (random-effects model; pooled HR = 1.65; 95% CI: 0.82--3.33; *p* = 0.077) ([Figure 3](#cancers-11-00778-f003){ref-type="fig"}b). In stratified analysis, according to data extraction method, *HOTAIR* was found to have a significant prognostic value irrespectively of the data source. that is, the HR reported in the articles (random-effects model: pooled HR = 2.05; 95% CI: 1.64--2.57; *p* \< 0.001) or extracted from the survival curves (fixed-effects model: pooled HR = 2.01; 95% CI: 1.75--2.30; *p* \< 0.001) ([Figure 3](#cancers-11-00778-f003){ref-type="fig"}c).

2.3. HOTAIR Overexpression Is Associated with Cancer Recurrence and Progression {#sec2dot3-cancers-11-00778}
-------------------------------------------------------------------------------

To investigate the relationship between *HOTAIR* expression and cancer recurrence or relapse, the recurrence-free survival (RFS) and disease-free survival (DFS) studies were combined; collectively accounting for 14 studies. Increased *HOTAIR* expression was found to be strongly related to cancer recurrence (pooled HR = 1.84; 95% CI = 1.28--2.64; *p* = 0.001). A random-effects model was applied because of the high heterogeneity (I^2^ = 83.5%; P~h~ \< 0.001) across studies ([Figure 2](#cancers-11-00778-f002){ref-type="fig"}b).

Furthermore, there are seven studies for combined metastasis-free survival (MFS) and progression-free survival (PFS). Of importance, high *HOTAIR* expression was predicted to be associated significantly with worse MFS/PFS (pooled HR = 2.60; 95% CI: 1.91--3.54; *p* \< 0.001). A fixed-effects model was used because of the relatively low heterogeneity (I^2^ = 46.6%; P~h~ = 0.081) ([Figure 2](#cancers-11-00778-f002){ref-type="fig"}c).

2.4. Publication Bias {#sec2dot4-cancers-11-00778}
---------------------

Publication bias was detected by Begg's funnel plot and Egger's test. There was no obvious asymmetry in Begg's funnel plots of OS, RFS/DFS, and MFS/PFS ([Figure 4](#cancers-11-00778-f004){ref-type="fig"}). Additionally, the *p*-values of Egger's tests were all greater than 0.05, indicating no potential publication bias (OS: *p* = 0.73; RFS/DFS: *p* = 0.70; MFS/PFS: *p* = 0.64).

2.5. Sensitivity Analysis {#sec2dot5-cancers-11-00778}
-------------------------

Sensitivity analyses did not indicate alterations in the results due to the inclusion of any individual study ([Figure 5](#cancers-11-00778-f005){ref-type="fig"}), that is, no single study affected the pooled HR or 95% CI.

2.6. TCGA-Derived Survival Curves {#sec2dot6-cancers-11-00778}
---------------------------------

To further the clinical relevance of our work and *HOTAIR* importance, we explored the possibility for any association of the *HOTAIR* expression to overall cancer survival. It was found that *HOTAIR* overexpression was significantly associated with worse OS in adrenocortical carcinoma (ACC), mesothelioma (MESO), and glioblastoma multiforme (GBM) ([Figure S1](#app1-cancers-11-00778){ref-type="app"}).

3. Discussion {#sec3-cancers-11-00778}
=============

*HOTAIR* exhibits pro-oncogenic activity since it has been shown to be overexpressed in numerous cancers and be implicated in several hallmarks of cancer, such as cellular proliferation, inhibition of apoptosis, genomic instability, angiogenesis, invasion, and metastasis \[[@B19-cancers-11-00778],[@B20-cancers-11-00778]\].

In the current study, an updated, comprehensive meta-analysis on the prognostic value of *HOTAIR* in various human cancers was presented. By applying stringent inclusion and exclusion criteria, we included 53 eligible studies, a relatively large number necessary for a meta-analysis to be considered robust. Previous meta-analyses on the association of *HOTAIR* with clinical outcome have included a rather limited number of studies with inconclusive and inconsistent findings \[[@B28-cancers-11-00778],[@B29-cancers-11-00778]\]. Other related studies have focused on certain types of cancers, such as head and neck squamous cell carcinoma \[[@B22-cancers-11-00778]\] or digestive system cancers \[[@B55-cancers-11-00778],[@B78-cancers-11-00778],[@B79-cancers-11-00778]\].

In the present study, we showed that there is a statistically significant relationship between elevated *HOTAIR* expression and poor OS. In the subgroup analysis, based on cancer type, *HOTAIR* was shown to be a significant predictor for worse prognosis for a variety of cancers, including solid cancers, such as urological cancers, head and neck neoplasms, cancers of the digestive system, and several female cancers (e.g., cervical, ovarian, and endometrial cancers), as well as the blood cancers, lymphoma and leukemia. Moreover, we complemented the findings from meta-analysis and further strengthened our hypotheses with survival information from other types of cancers, for which there were not any available eligible studies, retrieved from TCGA. It was found that there is, also, a strong relationship between *HOTAIR* overexpression and poor OS in neoplasms of the adrenal cortex, mesothelial neoplasms, and neuroepithelial tumors.

Taken together, the above findings lead to the suggestion that similar *HOTAIR*-mediated pathways might be implicated both in solid and liquid cancers \[[@B13-cancers-11-00778]\]. In particular, in several solid tumors, *HOTAIR* has been shown to exert its oncogenic and metastatic potential by mediating a repressive chromatin structure through the recruitment of histone-modifying or chromatin-remodeling complexes, such as PRC2 \[[@B14-cancers-11-00778],[@B16-cancers-11-00778],[@B31-cancers-11-00778]\]. For example, *HOTAIR* can promote pancreatic cancer cell proliferation by suppressing the expression of miR-663b via remodeling the chromatin structure within the miR-663b promoter \[[@B80-cancers-11-00778]\]. In a recent study, *HOTAIR* was also found to recruit PRC2 to catalyze H3K27 trimethylation to transcriptionally repress *E-cadherin* and promote EMT in gastric cancer \[[@B81-cancers-11-00778]\]. Similarly, high expression levels of *HOTAIR* and PRC2 proteins (H3K27 methylase EZH2, SUZ12, and EED) were found to be positively correlated with lymphomagenesis \[[@B82-cancers-11-00778]\]. In addition, *HOTAIR*, through miRNA sponging, contributes to carcinogenesis both in blood \[[@B60-cancers-11-00778]\] and solid tumors \[[@B83-cancers-11-00778],[@B84-cancers-11-00778]\]. However, there is a rather limited number of studies available on major cancers, such as breast neoplasms and respiratory tract cancers. Thus, more clinical trials on these cancers would enable us to better assess the relationship between *HOTAIR* expression and cancer patients' survival.

A positive correlation between *HOTAIR* and *CDKN1A* (*p21*) expression levels was also found ([Figure S2](#app1-cancers-11-00778){ref-type="app"}), suggesting a possible functional and/or physical association between *HOTAIR* and *CDKN1A* (*p21*) in cancer pathophysiology. From a clinical perspective, there is an emerging role of *CDKNIA* (*p21*), especially in cases where p53 is mutated like in many different solid tumors. The role of *p21* has been extensively viewed as an indicator of wildtype p53 activity \[[@B85-cancers-11-00778]\]. However, recent evidence suggests that upregulated *p21* can also act as an oncogenic factor in a p53-deficient environment, thereby driving a subset of atypical cancerous cells to more chemoresistant and aggressive phenotypes \[[@B86-cancers-11-00778]\]. Therefore, we cannot exclude a possible mechanistic association between *HOTAIR* and *p21* towards the negative regulation of target genes and a potential role in OS. Interestingly, recent studies have shown that *HOTAIR* expression was significantly higher in non-small-cell lung cancer (NSCLC) tissues compared to the adjacent normal tissues, and *HOTAIR* was negatively associated with p53 functionality rather than *p53* expression \[[@B87-cancers-11-00778]\]. In addition, *HOTAIR*, *p21*, and *p53* mRNA expression in doxorubicin- or γ rays-treated oral squamous cell carcinoma (OSCC) cells was up-regulated, indicating that the DNA damage response includes *HOTAIR* upregulation and may be closely connected to *p53* and *p21* expression and/or functionality \[[@B88-cancers-11-00778]\].

To investigate any possible effect of the genetic background and environment on the overall HRs, analyses were conducted based on the ethnic background of the participants. *HOTAIR* was found to be a powerful negative prediction biomarker for Asians. In the case of Caucasians, there was a link between *HOTAIR* overexpression and poor OS, albeit with moderate statistical significance; this is probably due to the relatively low number of available studies on patients of Caucasian origin. There were not, also, any available studies for other major ethnic groups, such as Africans or Indians, which would have further allowed us to estimate the influence of the genetic make-up on the association between *HOTAIR* and clinical outcome. The overall effect was similar in the stratified analysis according to data source, that is, the estimated HR reported in the articles or extrapolated from survival curves.

Therefore, high *HOTAIR* expression can predict an unfavorable clinical outcome in different types of cancers and possibly ethnic groups using different extraction methods. Notably, elevated expression of *HOTAIR* and prognosis in cancer patients is not particularly affected either by cancer type or even the patients' genetic background.

*HOTAIR* was found to be a poor predictor for both cancer recurrence and progression. The similar outcomes suggest that there are similar *HOTAIR*-dependent mechanisms underlying these two phenomena. In particular, *HOTAIR* was shown to mediate recurrence and progression in bladder cancer via the histone methyltransferase EZH2 \[[@B56-cancers-11-00778]\]. Similarly, enhanced *HOTAIR* expression was found to be associated both with progression and tumor recurrence in hepatocellular carcinoma by regulating the Wnt/β-catenin signal transduction pathway \[[@B89-cancers-11-00778]\].

*HOTAIR* has been demonstrated to promote tumor cell invasion and metastasis by modulating epithelial-to-mesenchymal transition (EMT) \[[@B16-cancers-11-00778],[@B46-cancers-11-00778],[@B90-cancers-11-00778]\]. Enhanced *HOTAIR* expression has also been shown to promote metastasis and invasion through different mechanisms including genome-wide re-targeting of PRC2 and subsequent epigenetic silencing of multiple anti-metastatic genes \[[@B14-cancers-11-00778]\], inhibition of the expression of the metastasis suppressor gene *E-cadherin* by recruiting the histone methyltransferase of PRC2, EZH2 \[[@B16-cancers-11-00778],[@B90-cancers-11-00778]\], targeting of Notch/Wnt signaling pathway-associated genes \[[@B91-cancers-11-00778]\], and upregulating chondroitin sulfotransferase CHST15 \[[@B92-cancers-11-00778]\], etc. *HOTAIR* also promotes invasion and migration by acting as a 'miRNA sponge', through targeting the corresponding miRNAs in the miR-1/CCND2 \[[@B93-cancers-11-00778]\], miR-148a/SNAIL2 \[[@B72-cancers-11-00778]\], and miR-23b/MAPK1 \[[@B94-cancers-11-00778]\] axes.

Heterogeneity was observed within the forest plots of OS and RFS/DFS, suggesting that HRs vary across studies. For this reason, the random-effects model was applied, where the overall HR was estimated based on the weighted average of the HRs of the individual studies. Given that the overall effect for OS and RFS/DFS was not affected by any single study, according to sensitivity analyses, we could suggest that, despite heterogeneity, the pooled HR can be considered quite reliable and representative.

Moreover, potential publication bias was not detected in the present meta-analysis, probably due to the sufficient representation of eligible studies in this meta-analysis.

4. Materials and Methods {#sec4-cancers-11-00778}
========================

4.1. Search Strategy and Study Eligibility Criteria {#sec4dot1-cancers-11-00778}
---------------------------------------------------

This systematic review and meta-analysis was conducted by following strictly the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines \[[@B95-cancers-11-00778]\].

The bibliographic database PubMed/MEDLINE \[[@B96-cancers-11-00778]\] was manually searched for published scientific studies on the associations between *HOTAIR* expression and prognosis in different types of cancers by using combinations of the relevant keywords: ("HOTAIR" OR "HOX transcript antisense RNA" or "HOXC cluster antisense RNA 4" or "HOXC-AS4" OR "HOXC11-AS1") and ("cancer" or "carcinoma" or "tumor" or "neoplasm" or "malignancy") and ("prognosis" or "survival" or "outcome" or "mortality" or "death"). The studies had to fulfill the following inclusion criteria so as to be considered eligible: (1) studies of human clinical trials, (2) studies including more than 30 patients in total, (3) the correlation between *HOTAIR* expression and cancer patients' survival was estimated, (4) availability of HR and 95% confidence interval (CI) or survival curves or sufficient data to calculate HR and 95% CI, (5) quantitative measurement (e.g., qPCR) of *HOTAIR* expression in cancers was included, and (6) studies published in English. Accordingly, the studies were excluded on the basis of the following exclusion criteria: (1) laboratory studies on animal models or cell lines; (2) reviews, meta-analyses, editorials, case reports, commentaries, unpublished data; (3) lack of sufficient data to estimate HR and 95% CI; and (4) samples other than tissue (e.g., blood, serum).

4.2. Study Selection, Data Extraction, and Quality Assessment {#sec4dot2-cancers-11-00778}
-------------------------------------------------------------

All potential studies were independently retrieved from the literature by two of the authors (H.I.T. and D.O.). Quality assessment of the studies was performed by H.I.T. and D.O. independently. Any disagreement was resolved by a third investigator (A.P.). Relevant data were extracted from the included studies and recorded into an ad hoc Excel worksheet. In the case that the HR was not reported in the corresponding article, the data were extracted from the graphical survival plots (i.e., Kaplan-Meier curves) by using the Engauge Digitizer v10.11 software, as previously described \[[@B97-cancers-11-00778]\].

4.3. Statistical Analyses {#sec4dot3-cancers-11-00778}
-------------------------

All statistical analyses were performed with STATA statistical software version 13.0 (Stata Corporation, College Station, TX, USA) and Microsoft Excel. The heterogeneity among the included studies was estimated by Higgins I-squared (I^2^) statistic as follows: I^2^ \< 25%; no heterogeneity; 25% \< I^2^ \< 50%: low heterogeneity; 50% \< I^2^ \< 75%: moderate heterogeneity; I^2^ \>75% high heterogeneity \[[@B98-cancers-11-00778],[@B99-cancers-11-00778]\]. In the case of statistically significant heterogeneity (I^2^ \> 50% and P~h~ \< 0.05), a random-effect model was applied, otherwise a fixed-effect model \[[@B100-cancers-11-00778],[@B101-cancers-11-00778]\] was used. Sensitivity analysis was performed by consecutive omission of individual studies to verify the consistency of outcomes. Potential publication bias was detected by Begg's funnel plot \[[@B102-cancers-11-00778]\] and Egger's test \[[@B103-cancers-11-00778]\]; a *p*-value less than 0.05 was indicative of statistically significant publication bias.

4.4. Bioinformatics Analysis {#sec4dot4-cancers-11-00778}
----------------------------

### 4.4.1. Survival Analysis {#sec4dot4dot1-cancers-11-00778}

Overall survival curves for different types of cancers were retrieved through the online tool GEPIA (Gene Expression Profiling Interactive Analysis) \[[@B104-cancers-11-00778]\], which provides survival analysis based on datasets obtained from The Cancer Genome Atlas (TCGA) (<https://tcga-data.nci.nih.gov>).

### 4.4.2. Correlation Analysis {#sec4dot4dot2-cancers-11-00778}

Correlation analysis between gene expression levels was performed through the web-based tool GEPIA \[[@B104-cancers-11-00778]\] which analyzes gene expression based on RNA sequencing (RNA-Seq) data from TCGA.

5. Conclusions {#sec5-cancers-11-00778}
==============

In this study, we have performed a meta-analysis complemented with bioinformatics analyses towards investigating the prognostic potential of the prominent lncRNA *HOTAIR* in cancer. On the basis of our findings, *HOTAIR* represents a potential powerful predictor of prognosis of overall survival, cancer recurrence, progression, and metastasis in multiple and diverse types of cancers. Therefore, *HOTAIR* could be applied in the clinical setting as a universal biomarker for monitoring cancer patient survival.

The following are available online at <https://www.mdpi.com/2072-6694/11/6/778/s1>, Figure S1: Kaplan-Meier plots depicting the prognostic potential of *HOTAIR* for OS in various types of cancers. (A) ACC; (B) MESO and (C) GBM. The corresponding HRs and *p*-values are indicated. The CIs are denoted by dashed lines, Figure S2: Correlation between *HOTAIR* and *CDKN1A* expression.

###### 

Click here for additional data file.
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![Flow chart of the process for study selection.](cancers-11-00778-g001){#cancers-11-00778-f001}

![Forest plots of combined analyses on the association of survival with *HOTAIR* expression. (**a**) Forest plot of OS analysis, (**b**) forest plot of RFS/DFS analysis, and (**c**) forest plot of MFS/PFS analysis. Abbreviations: HR, Hazard ratio; OS, overall survival; RFS, recurrence-free survival; DFS, disease-free survival; MFS, metastasis-free survival; and PFS, progression-free survival.](cancers-11-00778-g002){#cancers-11-00778-f002}

![Forest plots of combined analyses for overall survival (OS) associated with *HOTAIR* expression in different groups. (**a**) Forest plot for different types of cancers, (**b**) forest plot for different ethnic groups, and (**c**) forest plot for different data extraction methods.](cancers-11-00778-g003){#cancers-11-00778-f003}

![Begg's funnel plots of publication bias. (**a**) Begg's funnel plot of publication bias for OS; (**b**) Begg's funnel plot of publication bias for RFS/DFS; (**c**) Begg's funnel plot of publication bias for MFS/PFS. Each circle represents a separate study.](cancers-11-00778-g004){#cancers-11-00778-f004}

![Sensitivity analysis of each eligible study. (**a**) OS individual studies, (**b**) RFS/DFS individual studies and (**c**) MFS/PFS individual studies.](cancers-11-00778-g005){#cancers-11-00778-f005}

cancers-11-00778-t001_Table 1

###### 

Main characteristics of the studies included in the meta-analysis.

  Author, Year                                           Country          Cancer              Max. Follow-Up (Months)   Sample   Case Number   OS    DFS/RFS   MFS/PFS              Assay Method   Data Extraction Method                                                       
  ------------------------------------------------------ ---------------- ------------------- ------------------------- -------- ------------- ----- --------- -------------------- -------------- ------------------------ --------- -------------------- ------- ------------ ----------
  Gupta, 2010 \[[@B14-cancers-11-00778]\]                USA              Breast Cancer       240                       Tissue   44            88    132       2.76 (1.45--3.3)     0.036          NM                       NM        3.53 (2.78--4.89)    0.017   qRT-PCR      K-M
  Geng, 2011 \[[@B30-cancers-11-00778]\]                 China            HCC                 36                        Tissue   NM            NM    50        NM                   NM             2.24 (1.49--3.36)        0,049     NM                   NM      qRT-PCR      K-M
  Kogo, 2011 \[[@B31-cancers-11-00778]\]                 Japan            CRC                 60                        Tissue   20            80    100       5.62 (1.52--9.57)    0.008          NM                       NM        NM                   NM      qRT-PCR      reported
  Yang, 2011 \[[@B32-cancers-11-00778]\]                 China            HCC                 45                        Tissue   32            28    60        NM                   NM             3.56 (1.67--7.63)        0.001     NM                   NM      qRT-PCR      reported
  Lu, 2012 \[[@B33-cancers-11-00778]\]                   Italy            Breast Cancer       108                       Tissue   NM            NM    336       0.43 (0.21--0.89)    0.022          0.47 (0.26--0.87)        0.016     NM                   NM      qRT-PCR      reported
  Niinuma, 2012 \[[@B34-cancers-11-00778]\]              Japan            GIST                200                       Tissue   11            28    39        3.8 (0.7--21.2)      0.123          NM                       NM        NM                   NM      qRT-PCR      reported
  Chen, 2013 \[[@B24-cancers-11-00778]\]                 China            ESCC                60                        Tissue   27            51    78        2.40 (1.35--4.28)    0.003          NM                       NM        2.34 (1.22--4.48)    0.01    qRT-PCR      reported
  Endo, 2013 \[[@B17-cancers-11-00778]\]                 Japan            IGC                 68                        Tissue   23            13    36        0.63 (0.34--1.86)    0.137          NM                       NM        NM                   NM      qRT-PCR      K-M
  Endo, 2013 \[[@B17-cancers-11-00778]\]                 Japan            DGC                 60                        Tissue   20            12    32        3.08 (1.77--5.35)    \<0.01         NM                       NM        NM                   NM      qRT-PCR      K-M
  Ge, 2013 \[[@B35-cancers-11-00778]\]                   China            ESCC                100                       Tissue   90            47    137       3.16 (1.53--6.52)    0.002          NM                       NM        4.47 (1.99--10.06)   0.001   qRT-PCR      reported
  Ishibashi, 2013 \[[@B36-cancers-11-00778]\]            Japan            HCC                 36                        Tissue   13            51    64        2.84 (1.91--4.58)    0.041          NM                       NM        NM                   NM      qRT-PCR      K-M
  Li, 2013 \[[@B37-cancers-11-00778]\]                   China            LSCC                60                        Tissue   33            39    72        2.86 (1.15--7.07)    0.023          NM                       NM        NM                   NM      qRT-PCR      reported
  Li, 2013 \[[@B38-cancers-11-00778]\]                   China            ESCC                60                        Tissue   30            70    100       1.91 (1.06--3.99)    0.033          NM                       NM        NM                   NM      qRT-PCR      reported
  Liu, 2013 \[[@B39-cancers-11-00778]\]                  China            NSCLC               60                        Tissue   21            21    42        2.043 (0.91--4.58)   0.048          NM                       NM        NM                   NM      qRT-PCR      K-M
  Lv, 2013 \[[@B40-cancers-11-00778]\]                   China            ESCC                70                        Tissue   49            44    93        1.67 (1.02--2.79)    0.049          NM                       NM        NM                   NM      qRT-PCR      K-M
  Nakagawa, 2013 \[[@B21-cancers-11-00778]\]             Japan            NSCLC               50                        Tissue   17            60    77        NM                   NM             1.81 (1.09--3.74)        0,047     NM                   NM      qRT-PCR      K-M
  Nie, 2013 \[[@B41-cancers-11-00778]\]                  China            NPC                 82                        Tissue   91            69    160       1.9 (1.13--3.19)     0.012          1.41 (0.95--2.09)        0.47      1.92 (1.11--3.31)    0.018   qRT-PCR      K-M
  Sorensen, 2013 \[[@B42-cancers-11-00778]\]             Denmark          Breast Cancer       276                       Tissue   79            85    164       NM                   NM             NM                       NM        1.75 (1.13--2.71)    0.012   Microarray   reported
  Xu, 2013 \[[@B43-cancers-11-00778]\]                   China            Gastric cancer      75                        Tissue   56            27    83        0.47 (0.22--0.99)    0.04           NM                       NM        NM                   NM      qRT-PCR      reported
  He, 2014 \[[@B44-cancers-11-00778]\]                   China            EC                  48                        Tissue   62            83    145       3.04 (2.13--4.58)    0.026          NM                       NM        NM                   NM      qRT-PCR      K-M
  Huang, 2014 \[[@B45-cancers-11-00778]\]                China            Cervical cancer     55                        Tissue   109           109   218       2.86 (1.26--6.49)    0.012          NM                       NM        NM                   NM      qRT-PCR      reported
  Lee, 2014 \[[@B46-cancers-11-00778]\]                  Korea            Gastric cancer      48                        Tissue   28            20    48        NM                   NM             2.21 (0.53--9.16)        0.141     NM                   NM      qRT-PCR      reported
  Liu, 2014 \[[@B18-cancers-11-00778]\]                  China            Gastric cancer      48                        Tissue   39            39    78        2.7 (1.36--4.34)      0.023         NM                       NM        NM                   NM      qRT-PCR      K-M
  Okugawa, 2014 \[[@B47-cancers-11-00778]\]              Japan            Gastric cancer      60                        Tissue   77            73    150       1.77 (1.06--2.95)    0.028          NM                       NM        NM                   NM      qRT-PCR      reported
  Qiu, 2014 \[[@B48-cancers-11-00778]\]                  China            EOC                 79                        Tissue   32            32    64        1.87 (1.04--5.31)    0.041          2.54 (1.18--5.45)        0.034     NM                   NM      qRT-PCR      reported
  Svoboda, 2014 \[[@B49-cancers-11-00778]\]              Czech Republic   Colorectal cancer   54                        Tissue   36            37    73        4.46 (1.02--19.79)   0.048          NM                       NM        NM                   NM      qRT-PCR      reported
  Wu, 2014 \[[@B50-cancers-11-00778]\]                   China            Colon Cancer        72                        Tissue   40            80    120       3.92 (1.23--12.50)   0.021          NM                       NM        3.88 (1.37--10.98)   0.011   qRT-PCR      K-M
  Yan, 2014 \[[@B51-cancers-11-00778]\]                  China            Bladder Cancer      60                        Tissue   90            20    110       4.71 (2.89--8.71)    \<0.001        NM                       NM        NM                   NM      qRT-PCR      reported
  Heubach, 2015 \[[@B52-cancers-11-00778]\]              Germany          UHC                 200                       Tissue   27            81    108       2.20 (1.23--3.93)    0.008          NM                       NM        NM                   NM      qRT-PCR      reported
  Kim, 2015 \[[@B53-cancers-11-00778]\]                  Korea            Cervical cancer     60                        Tissue   89            22    111       NM                   NM             5.28 (1.01--27.74)       0,049     NM                   NM      qRT-PCR      reported
  Liu, 2015 \[[@B54-cancers-11-00778]\]                  China            Gastric cancer      40                        Tissue   24            37    61        NM                   NM             2.6 (1.74--3.89)         \<0.001   NM                   NM      qRT-PCR      K-M
  Ma, 2015 \[[@B55-cancers-11-00778]\]                   China            Gastric cancer      60                        Tissue   18            53    71        2.10 (1.10--4.03)    0.022          NM                       NM        NM                   NM      qRT-PCR      reported
  Martinez-Fernandez, 2015 \[[@B56-cancers-11-00778]\]   Spain            NMIBC               38                        Tissue   17            16    33        NM                   NM             NM                       NM        1.86 (0.58--5.96)    0.296   qRT-PCR      K-M
  Martinez-Fernandez, 2015 \[[@B56-cancers-11-00778]\]   Spain            NMIBC               38                        Tissue   30            33    63        NM                   NM             3.78 (2.40--5.96)        \<0.001   NM                   NM      qRT-PCR      K-M
  Qiu, 2015 \[[@B57-cancers-11-00778]\]                  China            SOC                 96                        Tissue   34            34    64        1.90 (1.01--3.56)    0.046          NM                       NM        NM                   NM      qRT-PCR      reported
  Wu, 2015 \[[@B58-cancers-11-00778]\]                   China            OSCC                60                        Tissue   25            25    50        1.91 (1.33--2.74)    \<0.001        NM                       NM        NM                   NM      qRT-PCR      K-M
  Wu, 2015 \[[@B59-cancers-11-00778]\]                   China            AML                 40                        Tissue   52            33    85        3.37 (0.99--8.31)    0.008          4.68 (2.81--7.79)        \<0.001   NM                   NM      qRT-PCR      reported
  Wu, 2015 \[[@B16-cancers-11-00778]\]                   China            OSCC                96                        Tissue   38            38    76        1.18 (0.68--2.84)    0.03           1.11 (0.78--2.54)        0.044     NM                   NM      qRT-PCR      reported
  Xing, 2015 \[[@B60-cancers-11-00778]\]                 China            AML                 36                        Tissue   68            68    136       2.03 (1.16--3.55)    0.007          0.61 (0.37--1.00)        0.034     NM                   NM      qRT-PCR      reported
  Zhang, 2015 \[[@B61-cancers-11-00778]\]                China            Gastric cancer      45                        Tissue   35            15    50        1.87 (1.46--2.1)     0.028          NM                       NM        NM                   NM      qRT-PCR      K-M
  Zhao, 2015 \[[@B62-cancers-11-00778]\]                 China            Gastric cancer      65                        Tissue   84            84    168       1.47 (1.04--2.06)    0.027          NM                       NM        NM                   NM      qRT-PCR      reported
  Luczak, 2016 \[[@B63-cancers-11-00778]\]               Poland           EC                  96                        Tissue   56            100   156       1.44 (0.81--3.19)    0.03           NM                       NM        NM                   NM      qRT-PCR      K-M
  Luo, 2016 \[[@B64-cancers-11-00778]\]                  China            Colon cancer        70                        Tissue   NM            NM    80        1.99 (1.4--2.8)      \<0.001        NM                       NM        NM                   NM      qRT-PCR      K-M
  Sun, 2016 \[[@B65-cancers-11-00778]\]                  China            Cervical cancer     50                        Tissue   49            10    59        1.31 (0.79--2.26)    0.02           NM                       NM        NM                   NM      qRT-PCR      K-M
  Yan, 2016 \[[@B66-cancers-11-00778]\]                  China            DLBCL               120                       Tissue   25            25    50        3.13 (1.22--8.04)    0.018          NM                       NM        NM                   NM      qRT-PCR      reported
  Zhang, 2016 \[[@B67-cancers-11-00778]\]                China            Acute leukemia      40                        Tissue   19            77    96        2.41 (1.25--4.62)    0.005          NM                       NM        NM                   NM      qRT-PCR      K-M
  Chen, 2017 \[[@B68-cancers-11-00778]\]                 China            Gastric cancer      62                        Tissue   33            32    65        1.99 (1.06--3.77)    0.033          NM                       NM        NM                   NM      qRT-PCR      reported
  Hu, 2017 \[[@B69-cancers-11-00778]\]                   China            RCC                 50                        Tissue   32            11    43        0.72 (0.20--2.55)    0.62           NM                       NM        NM                   NM      qRT-PCR      K-M
  Katayama, 2017 \[[@B70-cancers-11-00778]\]             Japan            RCC                 100                       Tissue   21            43    64        1.82 (1.06--3.88)    0.02           NM                       NM        NM                   NM      qRT-PCR      K-M
  Luan, 2017 \[[@B71-cancers-11-00778]\]                 China            MM                  60                        Tissue   30            30    60        1.36 (0.79--2.83)    0.01           NM                       NM        NM                   NM      qRT-PCR      K-M
  Xu, 2017 \[[@B72-cancers-11-00778]\]                   China            \* EC               36                        Tissue   20            20    40        2.69 (1.14--6.33)    0.032          NM                       NM        NM                   NM      qRT-PCR      K-M
  Zhang, 2017 \[[@B73-cancers-11-00778]\]                China            Thyroid cancer      60                        Tissue   NM            NM    35        2.21 (1.38--3.54)    0.001          NM                       NM        NM                   NM      qRT-PCR      reported
  Dong, 2018 \[[@B74-cancers-11-00778]\]                 China            Gastric cancer      60                        Tissue   22            10    32        2.26 (0.74--6.89)    0.158          NM                       NM        NM                   NM      qRT-PCR      K-M
  Huang, 2018 \[[@B75-cancers-11-00778]\]                China            Colorectal cancer   110                       Tissue   26            26    52        2.56 (0.91--7.35)    \<0.01         NM                       NM        NM                   NM      qRT-PCR      reported
  Xiao, 2018 \[[@B76-cancers-11-00778]\]                 China            Colorectal cancer   60                        Tissue   52            52    104       1.45 (0.87--2.43)    0.041          NM                       NM        NM                   NM      qRT-PCR      K-M

Abbreviations: OS, overall survival; RFS, recurrence-free survival; DFS, disease-free survival; MFS, metastasis-free survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; qRT-PCR, quantitative reverse transcription polymerase chain reaction; NM: not mentioned; K-M, Kaplan-Meier plot; AML, acute myeloid leukemia; CRC, colorectal cancer; DGC, diffuse gastric cancer; DLBCL, diffuse large B cell lymphoma; ESCC, esophageal squamous cell carcinoma; EC, endometrial carcinoma; EOC, epithelial ovarian cancer; \* EC, esophageal cancer; GIST, gastrointestinal stromal tumors; HCC, hepatocellular carcinoma; IGC, intestinal gastric cancer; LSCC, laryngeal squamous cell carcinoma; MM, malignant melanoma; NSCLC, non-small cell lung cancer; NPC, nasopharyngeal carcinoma; NMIBC, non-muscle-invasive bladder cancer; OSCC, oral squamous cell carcinoma; RCC, renal cell carcinoma; SOC, serous ovarian cancer; and UHC, urothelial carcinoma.
